Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia：a Multi-center, Open-label, Non-randomised, Single-arm Phase Ⅰ Clinical Trial

NCT06326021 is registered in ClinicalTrials.gov with Beijing GoBroad Hospital as lead sponsor.

NCT NCT06326021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06326021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia：a Multi-center, Open-label, Non-randomised, Single-arm Phase Ⅰ Clinical Trial
Lead sponsor
Beijing GoBroad Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
April 2, 2024
Completion date
December 30, 2026
Enrollment
27 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

refractory/relapsed acute myeloid leukaemia